Moderna (MRNA) stock rises 4.37% as the company launches Phase 1 human trials for its Bundibugyo Ebola vaccine in Canada with $50M CEPI funding support. The post Moderna (MRNA) Stock Climbs as Company Launches Ebola Vaccine Trial in Canada appeared first on Blockonomi.